Formulation and evaluation of NLCS encapsulated with S-Allyl-L-Cysteine Sulfoxide for treatment of inflammatory bowel disease

Inflammatory Bowel Disease (IBD) is an autoimmune disorder of the gastrointestinal tract that includes two entities, Crohn's disease and ulcerative colitis. The main cause includes inflammation and generation of reactive oxygen species. S-Allyl-L-Cysteine Sulfoxide (ACSO), an active constituent obtained from Allium Sativum possess antioxidant and anti-inflammatory activities and found to reduce the inflammation by inhibiting cell-mediated Th-1 and inflammatory cytokines such as TNF-alpha, IL-1alpha, IL-6, T-cell IFN-gamma. ACSO entrapped with in NLCs for treatment of IBD. The nine formulations (NLCs-1-NLCs-9) of ACSO entrapped with in NLCs were characterized for morphological parameters, PDI, entrapment efficiency, in vitro drug release. The size and PDI of NLCs-7 and NLCS-9 found to be 186 ± 4nm, 0.28 ± 0.10 and 178 ± 6nm, 0.22 ± 0.4, with entrapment efficiency of 84 and 91%, respectively. In vivo activity was evaluated in IBD induced rat model. These findings were supported by the histopathological characteristics. Observation revealed inhibition in reduction of inflammation and production of inflammatory cytokines. The result assures that ACSO -NLCs could be easily utilized for treating root cause of IBD.